Xenon Pharmaceuticals Inc.
XENE NASDAQHealthcare ★★★★★Latest Earnings
Date
Aug 6, 2026
ET
EPS Est.
-1.14
EPS Actual
-1.11
Revenue Est.
$1.7M
Revenue Actual
--
Next Earnings Report
Date
Nov 2, 2026 · Mon
Time
Your time zone matches ET
After-market(ET)
Fiscal Period
FY2026 Q3
EPS Est.
-1.17
Revenue Est.
$1.3M
Company Overview
Xenon Pharmaceuticals Inc. (ticker XENE) is listed on NASDAQ with a market cap of about $5.87B. Its next earnings report (FY2026 Q3) is expected on Nov 2, 2026 (ET), After-market, with consensus EPS of -1.17. In the last 15 reported quarters, EPS beat consensus estimates 9 times.
Actual EPS TrendRecently15Term · Mar 1, 2023 → Aug 6, 2026
Mar 1, 2023Range: -1.31 ~ -0.57Aug 6, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Aug 6, 2026 | -- | -1.14 | -1.11 | $1.7M | -- |
| May 7, 2026 | -- | -1.17 | -1.17 | $1.4M | -- |
| Feb 26, 2026 | -- | -1.20 | -1.31 | $-178571 | -- |
| Nov 3, 2025 | -- | -1.16 | -1.15 | -- | -- |
| Aug 11, 2025 | -- | -1.03 | -1.07 | -- | -- |
| May 12, 2025 | -- | -0.94 | -0.83 | $1.9M | $7.5M |
| Feb 27, 2025 | -- | -0.89 | -0.84 | $312500 | -- |
| Nov 12, 2024 | -- | -0.82 | -0.81 | $294120 | -- |
| Aug 8, 2024 | -- | -0.72 | -0.75 | -- | -- |
| May 9, 2024 | -- | -0.69 | -0.62 | -- | -- |
| Feb 29, 2024 | -- | -0.76 | Above forecast↑-0.64 | $1.9M | $5.4M |
| Nov 8, 2023 | -- | -0.75 | -0.73 | $2.3M | -- |
| Aug 9, 2023 | -- | -0.69 | -0.72 | $400000 | -- |
| May 9, 2023 | -- | -0.62 | -0.63 | $570000 | -- |
| Mar 1, 2023 | -- | -0.58 | -0.57 | $2.9M | $8766 |
Original Filings (SEC)
Quarterly10-Q · 2026-08-06 ↗
Earnings Release8-K · 2026-08-06 ↗
Quarterly10-Q · 2026-05-07 ↗
Earnings Release8-K · 2026-05-07 ↗
Annual10-K · 2026-02-26 ↗
Earnings Release8-K · 2026-02-26 ↗
Quarterly10-Q · 2025-11-03 ↗
Earnings Release8-K · 2025-11-03 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
